Acute pancreatitis is widely considered as a harmful risk after endoscopic papillo-sphincterotomy (EST). Recently somatostatin, which decreases both pancreatic flow rate and enzyme output, has been reported to prevent serum enzyme elevation after ERCP. The aim of this study was to evaluate in 54 patients, who underwent EST and received either somatostatin (i.v. 250 μg/hr for 26 hours) or isotonic saline as placebo, the effect of the hormone on enzymatic elevation. Eighteen hours after EST, somatostatin decreased the enzymatic elevation by about 30% in comparison with the placebo group; in patients with a history of recurrent pancreatitis the decrease was about 40%. However, these differences were not statistically significant. Severe pancreatic reaction occurred in 2 cases of the somatostatin group and in 5 cases of the control group. In conclusion our data suggest that the use of somatostatin shows a negligible variation in enzymatic rise in unselected patients, however, the hormone may be useful in patients with recurrent pancreatitis. However, when a papillary oedema is the probable cause of a marked reduction of pancreatic juice flow, the infusion of somatostatin seems to be only partially effective in preventing major complications.
|Number of pages||4|
|Journal||Italian Journal of Gastroenterology|
|Publication status||Published - 1988|
ASJC Scopus subject areas